Multiple Sclerosis (MS) is a condition where the immune system attacks the brain and spinal cord. This study is testing a new medicine called Frexalimab on people with relapsing MS, where symptoms come and go. It will compare Frexalimab to another drug called teriflunomide to see which works better at reducing relapses (times when symptoms get worse).

The study is for adults aged 18 to 55 with relapsing MS. It lasts about 40 months for early participants and about 20 months for those joining later. Participants will have visits every 4 weeks for the first 6 months and then every 3 months afterward. They will have a total of 4 main visits.

• The study lasts between 12 to 40 months.
• Participants need to visit the study site regularly.
• Eligibility depends on past MS relapses and other health factors.

This is a chance to try a new treatment but involves commitment and regular check-ups. Understanding the risks and benefits is important before joining.